Skip to main content
SpringerLink
Log in

Time Course of Response to Antidepressants in Late-Life Major Depression

Therapeutic Implications

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

In the treatment of depression, there is considerable interest in the time course of response and, in particular, the speed with which individuals recover from depressive episodes. Examination of the time course and speed of response is critical for assessing the usefulness of specific treatments. However, while this issue has received attention in mid-life adult populations, it has received little consideration in the context of late-life major depression. The synthesis of empirical reports indicates that, while older adults with depression seem to respond with the same speed as mid-life adults, several factors have consistently been associated with reduced speed of response to antidepressant treatment, including greater severity of depressive symptoms and co-occurring anxiety symptoms. Limited evidence suggests that sleep impairment and genetic factors (e.g. presence of the s allele of the serotonin transporter gene promoter region) may also be associated with reduced speed of response. Some factors have consistently been found to be unrelated to speed of response (demographic characteristics, nonpsychiatric physical illnesses) whereas other factors have only mixed evidence supporting any effect (psychosocial and other clinical factors). While there is little work available to date, some evidence suggests that time course and speed of response affect longer-term outcomes of depression pharmacotherapy; thus, older adults with more rapid versus slower patterns of response may differ in the types of maintenance treatment needed to avert additional depressive episodes.

None of potential strategies for accelerating speed of response have been clearly shown to be effective in late-life depression. Future treatment studies for late-life depression should routinely consider not only overall efficacy of a given pharmacotherapy (i.e. total rate of response), but time course and speed of response. To this end, new investigations must be designed to overcome the methodological limitations of prior studies that have examined time course and they should include a range of potential covariates and outcomes of between-patient differences in speed of response. Better understanding of factors related to such differences may suggest new intervention strategies to accelerate response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Fig. 2
Table IV

Similar content being viewed by others

References

  1. Muller H, Moller HJ. Methodological problems in the estimation of the onset of the antidepressant effect. J Affect Disord 1998; 48: 15–23

    Article  PubMed  CAS  Google Scholar 

  2. Thase ME. Methodology to measure onset of action. J Clin Psychiatry 2001; 62(15 Suppl.): 18–21

    Google Scholar 

  3. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001; 18: 355–68

    Article  PubMed  CAS  Google Scholar 

  4. Reynolds III CF. Treatment of major depression in later life: a life cycle perspective. Psychiatr Q 1997; 68: 221–46

    Article  PubMed  Google Scholar 

  5. Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 2001; 62(4 Suppl.): 12–6

    PubMed  CAS  Google Scholar 

  6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62

    Article  PubMed  CAS  Google Scholar 

  7. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 143: 382–9

    Article  Google Scholar 

  8. Guy W, editor. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, 1976; Publication ADM 76–338: 218–22

  9. Ackerman DL, Greenland S, Bystritsky A, et al. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol 2000; 20: 658–65

    Article  PubMed  CAS  Google Scholar 

  10. Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157: 729–36

    Article  PubMed  CAS  Google Scholar 

  11. Evans M, Hammond M, Wilson K, et al. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry 1997; 12: 817–24

    Article  PubMed  CAS  Google Scholar 

  12. Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs fluoxetine in patients aged 70 or over with major depression. Am J Geriatr Psychiatry 1999; 7: 221–7

    Article  PubMed  CAS  Google Scholar 

  13. Kyle CJ, Petersen HEH, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitryptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8: 147–53

    Article  PubMed  CAS  Google Scholar 

  14. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10: 541–50

    PubMed  Google Scholar 

  15. Schöne W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13(2 Suppl.): 34–9S

    Google Scholar 

  16. Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002; 63: 694–9

    Article  PubMed  CAS  Google Scholar 

  17. Forlenza OV, Almeida OP, Stoppe A, et al. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001; 13: 75–84

    Article  PubMed  CAS  Google Scholar 

  18. Karlsson I, Godderis J, Augusto De Mendonca Lima C, et al. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with and without mild to moderate dementia. Int J Geriatr Psychiatry 2000; 15: 295–305

    Article  PubMed  CAS  Google Scholar 

  19. Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9: 406–14

    PubMed  CAS  Google Scholar 

  20. Navarro V, Gastó C, Torres X, et al. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 2001; 103: 435–40

    Article  PubMed  CAS  Google Scholar 

  21. Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61: 559–68

    Article  PubMed  CAS  Google Scholar 

  22. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160(7): 1277–85

    Article  PubMed  Google Scholar 

  23. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995; 7: 89–104

    Article  PubMed  CAS  Google Scholar 

  24. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994; 9: 245–50

    Article  PubMed  CAS  Google Scholar 

  25. Reynolds III CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry 1996; 153: 1288–92

    PubMed  Google Scholar 

  26. Alexopoulos GS, Meyers BS, Young RC, et al. Recovery in geriatric depression. Arch Gen Psychiatry 1996; 53: 305–12

    Article  PubMed  CAS  Google Scholar 

  27. Kirsch I, Moore TJ, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevent Treat 2002; 5: Article 23, Epub 2002 Jul 15

  28. Miller FE. Strategies for the rapid treatment of depression. Hum Psychopharmacol 2001; 16: 125–32

    Article  PubMed  Google Scholar 

  29. Flint AJ, Rifat SL. Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Depress Anxiety 1997; 5: 103–7

    Article  PubMed  CAS  Google Scholar 

  30. Karp JF, Frank E, Anderson B, et al. Time to remission in late-life depression: analysis of effects of demographic, treatment, and life-events measures. Depression 1993; 1: 250–6

    Article  Google Scholar 

  31. Dew MA, Reynolds III CF, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54: 1016–24

    Article  PubMed  CAS  Google Scholar 

  32. Gildengers AG, Houck PR, Mulsant BH, et al. Course and rate of antidepressant response in the very old. J Affect Disord 2002; 69: 177–84

    Article  PubMed  Google Scholar 

  33. Reynolds III CF, Frank E, Dew MA, et al. Treatment of 70(+)-year-olds with recurrent major depression. Am J Geriatr Psychiatry 1999; 7: 64–9

    PubMed  Google Scholar 

  34. Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989; 28: 1–9

    Article  PubMed  CAS  Google Scholar 

  35. Gildengers AG, Houck PR, Mulsant BH, et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharm. In press

  36. Meyers BS, Sirey JA, Bruce M, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002; 59: 729–35

    Article  PubMed  Google Scholar 

  37. Birkenhager TK, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord 2003 Apr; 74(2): 191–5

    Article  PubMed  Google Scholar 

  38. Reynolds III CF, Dew MA, Frank E, et al. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998; 155: 795–9

    PubMed  Google Scholar 

  39. Szanto K, Mulsant BH, Houck P, et al. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60: 610–7

    Article  PubMed  Google Scholar 

  40. Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998; 13: 717–26

    Article  PubMed  CAS  Google Scholar 

  41. Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000; 157: 722–8

    Article  PubMed  CAS  Google Scholar 

  42. Lenze EJ, Mulsant BH, Shear MK, et al. Anxiety symptoms in elderly patients with depression: what is the best approach to treatment? Drugs Aging 2002; 19: 753–60

    Article  PubMed  Google Scholar 

  43. Mulsant BH, Reynolds CF, Shear MK, et al. Comorbid anxiety disorders in late-life depression. Anxiety 1996; 2: 242–7

    Article  PubMed  CAS  Google Scholar 

  44. Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord 2003; 77(3): 247–54

    Article  PubMed  Google Scholar 

  45. Grunhaus L, Rabin D, Greden JF. Simultaneous panic and depressive disorder: response to antidepressant treatments. J Clin Psychiatry 1986; 47: 4–7

    PubMed  CAS  Google Scholar 

  46. Arve S, Tilvis RS, Lehtonen A, et al. Coexistence of lowered mood and cognitive impairment of elderly people in five birth cohorts. Aging 1999; 11: 90–5

    PubMed  CAS  Google Scholar 

  47. Magni G, Palazzolo O, Bianchin G. The course of depression in elderly outpatients. Can J Psychiatry 1988; 33: 21–4

    PubMed  CAS  Google Scholar 

  48. Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999; 56: 713–8

    Article  PubMed  CAS  Google Scholar 

  49. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57: 285–90

    Article  PubMed  CAS  Google Scholar 

  50. Agbayewa MO. Outcome of depression in a geriatric medical day hospital following psychiatric consultation. Int J Geriatr Psychiatry 1990; 5: 33–9

    Article  Google Scholar 

  51. Burvill PW, Hall WD, Stampfer HG, et al. The prognosis of depression in old age. Br J Psychiatry 1991; 158: 64–71

    Article  PubMed  CAS  Google Scholar 

  52. Baldwin RC, Benbow SM, Mariott A, et al. Depression in old age: a reconsideration of cerebral disease in relation to outcome. Br J Psychiatry 1993; 163: 82–90

    Article  PubMed  CAS  Google Scholar 

  53. Knowles JB, MacLean AW. Age-related changes in sleep in depressed and healthy subjects: a meta-analysis. Neuropsychopharm 1990; 3: 251–9

    CAS  Google Scholar 

  54. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–90

    Article  PubMed  CAS  Google Scholar 

  55. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9

    Article  PubMed  CAS  Google Scholar 

  56. Small GW, Hamilton SH, Bystritsky A, et al. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995; 7 Suppl.: 41–53

    Article  PubMed  Google Scholar 

  57. Salloway S, Boyle PA, Correia S, et al. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. Am J Geriatr Psychiatry 2002; 10: 107–11

    PubMed  Google Scholar 

  58. Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 1998; 28: 1015–26

    Article  PubMed  CAS  Google Scholar 

  59. Hickie I, Scott E, Mitchell P, et al. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995; 37: 151–60

    Article  PubMed  CAS  Google Scholar 

  60. Miller MD, Lenze EJ, Dew MA, et al. Effect of cerebrovascular risk factors on depression treatment outcome in later life. Am J Geriatr Psychiatry 2002; 10: 592–8

    PubMed  Google Scholar 

  61. Mulder RT. Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002; 159: 359–71

    Article  PubMed  Google Scholar 

  62. Reynolds III CF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281: 39–45

    Article  PubMed  CAS  Google Scholar 

  63. Dew MA, Reynolds CF, Mulsant BH, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord 2001; 65: 155–66

    Article  PubMed  CAS  Google Scholar 

  64. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782–6

    Article  PubMed  CAS  Google Scholar 

  65. Quitkin FM, Rabkin JG, Markowitz JM, et al. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987; 44: 259–64

    Article  PubMed  CAS  Google Scholar 

  66. Pinder RM. Depression: the relevance of the time factor. J Clin Psychiatry 2001; 62(15 Suppl.): 5–7

    PubMed  Google Scholar 

  67. Parker G, Roy K, Menkes DB, et al. How long does it take for antidepressant therapies to act? Aust N Z J Psychiatry 2000; 34: 65–70

    Article  PubMed  CAS  Google Scholar 

  68. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3: 127–35

    Article  PubMed  CAS  Google Scholar 

  69. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response: a review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–22

    Article  PubMed  CAS  Google Scholar 

  70. Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 1980; 137: 963–5

    PubMed  CAS  Google Scholar 

  71. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152: 929–31

    PubMed  CAS  Google Scholar 

  72. Kaufmann MW, Cassem NH, Murray GB, et al. The use of methylphenidate in depressed patients after cardiac surgery. J Clin Psychiatry 1984; 45: 82–4

    PubMed  CAS  Google Scholar 

  73. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9: 298–303

    PubMed  CAS  Google Scholar 

  74. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychpharmacol 2003; 13: 57–66

    Article  CAS  Google Scholar 

  75. Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000; 12(1 Suppl.): 63–8

    Article  PubMed  Google Scholar 

  76. Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of ‘vascular depression’. Int J Geriatr Psychiatry 2001; 16: 254–60

    Article  PubMed  CAS  Google Scholar 

  77. Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. Arch Gen Psychiatry 1997; 54: 915–22

    Article  PubMed  CAS  Google Scholar 

  78. Green TD, Reynolds III CF, Mulsant BH, et al. Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptyline, or placebo. J Geriatr Psychiatry Neurol 1999; 12: 67–71

    Article  PubMed  CAS  Google Scholar 

  79. Smith GS, Reynolds III CF, Houck PR, et al. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry 2002; 10: 561–7

    PubMed  Google Scholar 

  80. Reynolds III CF. Effects of therapeutic sleep deprivation on speed of antidepressant response in elderly depressed patients. Annual Meeting of the American Association of Geriatric Psychiatry; 2003 Mar 3–5, Honolulu

  81. Sumaya IC, Rienzi BM, Deegan II JF, et al. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. J Gerontol Biol Sci Med Sci 2001; 56: M356–60

    Article  CAS  Google Scholar 

  82. Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry 2003; 64: 648–53

    Article  PubMed  CAS  Google Scholar 

  83. Kobak KA, Greist JH, Jefferson JW, et al. New technologies to improve clinical trials. J Clin Psychopharmacol 2001; 21: 255–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This manuscript was supported by grants MH60473, MH19986, MH52247, MH37860 and MH43832 from the National Institute of Mental Health, Rockville, MD, USA.

Dr Lenze has received research support from Forest Laboratories, Janssen Pharmaceuticals and Pfizer Inc. Dr Bharucha is a member of the speakers bureau of Pfizer Inc. and Forest Laboratories. Dr Mulsant has received honoraria and/or research support from Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Pfizer Inc. and Solvay. Dr Reynolds has received research support from GlaxoSmithKline, Forest Laboratories and Pfizer Inc.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 O’Hara Street, Pittsburgh, Pennsylvania, 15213, USA

    Ellen M. Whyte,  Mary Amanda Dew, Ariel Gildengers, Eric J. Lenze, Ashok Bharucha, Benoit H. Mulsant & Charles F. Reynolds III

  2. Pittsburgh Veterans Administration Healthcare System, Pittsburgh, Pennsylvania, USA

    Ellen M. Whyte & Benoit H. Mulsant

  3. Department of Psychology, University of Pittsburgh, Pittsburgh, USA

    Mary Amanda Dew

  4. Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA

    Mary Amanda Dew

Authors
  1. Ellen M. Whyte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Amanda Dew
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ariel Gildengers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric J. Lenze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashok Bharucha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benoit H. Mulsant
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charles F. Reynolds III
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Amanda Dew.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whyte, E.M., Dew, M.A., Gildengers, A. et al. Time Course of Response to Antidepressants in Late-Life Major Depression. Drugs Aging 21, 531–554 (2004). https://doi.org/10.2165/00002512-200421080-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421080-00004

Keywords

Search

Navigation